Trastuzumab

Costs of Breast Cancer Chemotherapy Vary Widely in the United States

Costs of Breast Cancer Chemotherapy Vary Widely in the United States

Researchers found wide variances in the cost of breast cancer chemotherapy, depending on the course of treatment selected.

Trastuzumab Biosimilar Comparable the Monoclonal Antibody for Advanced HER2+ Breast Cancer

By

MYL-1401O is comparable in efficacy and safety to the anti-HER2 monoclonal antibody trastuzumab as frontline therapy in breast cancer.

All Patients Need Monitoring for Heart Events After Trastuzumab Therapy for Breast Cancer

All Patients Need Monitoring for Heart Events After Trastuzumab Therapy for Breast Cancer

By

Patients undergoing treatment for breast cancer with trastuzumab-containing regimens need to be monitored for heart damage regardless of age.

Single-dose Trastuzumab Kick Starts Immune Response in Some Breast Cancers

By

Women with the HER2-enriched type of HER2-positive breast cancer had the highest rate of immune response to treatment with trastuzumab, with a significant increase after just 1 dose of the drug.

Antibody-drug Conjugates Show Potential in Breast Cancer

By

Research in mouse models has identified molecules that can bind to cancer cells and induce apoptosis.

Trastuzumab improves long-term survival of HER2-positive breast cancer patients

By

Trastuzumab significantly improves the long-term survival of HER-2 positive breast cancer patients, according to a large national study.

Updated results shows SC trastuzumab as safe and effective as IV formulation

Updated results shows SC trastuzumab as safe and effective as IV formulation

Researchers have found that subcutaneous trastuzumab has a similar safety profile and similar event-free survival rate with intravenous trastuzumab.

Trastuzumab shows benefit years after treatment for HER2+ breast cancer

By

The addition of trastuzumab to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer.

Benefit seen for adding trastuzumab to breast cancer chemotherapy

Benefit seen for adding trastuzumab to breast cancer chemotherapy

Herceptin in addition to chemotherapy boosts survival, reduces risk of cancer recurrence

Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study confirms use of trastuzumab for HER2-positive breast cancer

By

The use of trastuzumab (Herceptin) as the standard-of-care treatment for HER2-positive breast cancer has been supported by the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study.

Benefits of trastuzumab outweigh risk of harm for advanced breast cancer

By

In women with advanced (or metastatic) breast cancer, treatment with the breast cancer drug trastuzumab is associated with prolonged survival but also increases the risk of developing heart problems

Trastuzumab benefit predicted by high levels of immune cells in breast cancer tumors

By

Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab. These results were presented at the 2013 San Antonio Breast Cancer Symposium.

New technique allows breast cancer drugs to cross the blood-brain barrier

By

A new approach selectively permeabilizes the blood-brain barrier at sites of brain metastases, even those 200 times smaller than currently detectable in the clinic.

Everolimus overcomes trastuzumab resistance in HER2+ early breast cancer

By

Some patients with early breast cancer had a benefit in clinical response rate when everolimus was added to trastuzumab treatment, though the benefit was statistically nonsignificant. These puzzling results suggested that this benefit was independent of the molecular pathways that could be expected to be involved.

Trastuzumab: not just for HER2-positive breast cancer anymore?

The monoclonal antibody trastuzumab (Herceptin) may be effective against HER2-negative breast cancers in addition to HER2-positive disease.

Trastuzumab may also be effective for women with HER2-negative breast cancer

By

The protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative. The drug trastuzumab (Herceptin), which targets HER2, may have an even greater role for treating breast cancer and preventing its spread.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs